Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 98.00
Bid: 96.00
Ask: 100.00
Change: -7.00 (-6.80%)
Spread: 4.00 (4.167%)
Open: 103.00
High: 96.00
Low: 96.00
Prev. Close: 103.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Diaceutics wins two deals; Faron proposes placing

Fri, 27th Jan 2023 18:56

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Diaceutics PLC - Belfast-based testing laboratories company - Signs two enterprise-level, multi-disease data engagements with two pharmaceutical companies with a combined value of USD7 million over a two-year period. Says that the agreements are for its subscription data services. Reports that revenue in 2022 increased 44% to GBP20.0 million from GBP13.9 million in 2021. Adds that revenue is materially ahead of market expectations. Expects earnings before interest, tax, depreciation, and amortization to be in line with market expectations, with an with Ebitda margin similar to 2021. Attributes growth to demand from its pharmaceutical and life science customers.

----------

ICG-Longbow Senior Secured UK Property Debt Investments Ltd - Resolves to return 5.50 pence per ordinary share to shareholders, being GBP6.7 million in total based on the current number of ordinary shares in issue.

----------

Ilika PLC - Hampshire, England-based solid-state battery technology provider - Reports that it is leading a 24-month GBP8.2 million Faraday Battery Challenge collaboration programme "to integrate high silicon content electrodes into its Goliath solid-state batteries to enable automotive level performance". Adds that it will receive a GBP2.8 million grant over the 24-month programme.

----------

Mercia Asset Management PLC - Warwickshire, England-based, regionally-focused asset manager - Says that the final payment of GBP2.1million in relation to its acquisition of a venture capital trust fund management business from NVM Private Equity LLP has become payable. Plans to pay through the issue of 6.5 million new deferred consideration shares at 32.45p each. Expects the deferred consideration shares to start trading on AIM on January 31.

----------

Time Out Group PLC - media and hospitality business - Signs a lease deal with Klepierre Real Estate Espana SLU to open market in Barcelona in the first half of 2024. Says that Time Out Market Barcelona will be located in the Maremagnum shopping and leisure destination in the Port Vell, across 56,500 square feet. Says that this opening increases the line-up of new sites to eight markets in development which are set to open between 2023 and 2027. Does not disclose any details about the lease. "Barcelona is globally regarded as one of the top food destinations in the world and is a perfect fit for our brand. We are excited to bring Time Out Market to this fabulous, vibrant city together with our partners Klepierre and Estrella Damm. We now have an incredibly strong line-up of new Markets that will open in the next few years and with interest from landlords and real estate developers stronger than ever, we expect to further accelerate the signing of new Markets in the year ahead," Co-CEO Jay Coldren says.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based biopharmaceutical drug discovery and development company - Proposes a private placing to raise EUR11.0 million through an accelerated book-building directed at institutional and other investors. Adds that the subscription price per placing share is to be determined on the basis of the bids received in the bookbuild in euros. Says the Finland Branch of Carnegie Investment Bank AB is acting as sole bookrunner and lead manager in the placing.

----------

By Abby Amoakuh, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
12 Jul 2019 10:20

Faron Pharma Pleased By MATINS Progress And Plans To Increase Capacity

(Alliance News) - Faron Pharmaceuticals Oy said on Friday its MATINS study of nine cancer patients is progressing well, and it is planning to expand the clinical trial to more countries.The

Read more
26 Jun 2019 11:52

Faron Pharmaceuticals Says Traumakine Study Hindered By Steroid Use

(Alliance News) - Faron Pharmaceuticals Oy on Wednesday said interim results from its phase two Inforaaa study support continuation but the study is limited by a lack of patients not also taking a

Read more
14 Jun 2019 11:54

Faron Pharmaceuticals' Analysis Explains "Disappointing" Prior Trial

(Alliance News) - Faron Pharmaceuticals Oy on Friday said analysis of a more recent trial of Traumakine has explained why the drug did not perform as expected in a previous trial.Shares in

Read more
14 Jun 2019 10:37

Faron Pharmaceuticals reports 'significant' findings from YODA study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced results from its pharmacokinetic/dynamic 'YODA' study examining the administration of concomitant steroids and Traumakine in healthy volunteers on Friday.

Read more
24 May 2019 13:34

Faron Pharma Finance Head Wichmann Steps Down, Hanninen Replaces

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Friday said it has made several managerial changes, which it believes will strengthen its operating performance.The clinical stage said

Read more
24 May 2019 11:50

Faron appoints new CFO after some internal shuffling

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals updated the market on its board and management team on Friday, announcing that Yrjö Wichmann was leaving his current role as its chief financial officer to take up the new position of vice-president, financing and investor relations.

Read more
14 May 2019 14:16

Faron Pharmaceuticals Raises EUR1.3 Million Via Share Subscription (ALLISS)

LONDON (Alliance News) - Biopharmaceutical company Faron Pharmaceuticals Ltd said Tuesday that it has raised EUR1.3 million via share subscription.The company has issued 1.8 million shares

Read more
7 May 2019 11:44

Faron Pharmaceuticals Narrows Loss On Reduced Clinical Trial Costs

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Tuesday reported a slightly narrowed annual loss as the drug developer's research & development costs fell.Faron is a clinical

Read more
2 May 2019 17:30

Faron Pharmaceuticals Knows Of No Reason For 43% Share Price Jump

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it is unable to explain the recent movement in its share price.Faron noted Thursday's 43% share price rise, and said

Read more
30 Apr 2019 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 1 May J SainsburyFull Year ResultsConnect GroupHalf Year GroupQ1 Stock

Read more
29 Apr 2019 15:46

Faron Gets Results Of Traumakine Study From Japanese Licensing Partner

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said its Japanese licensing partner Maruishi Pharmaceutical Co Ltd has provided clinical trial results on its phase three Traumakine for

Read more
11 Apr 2019 12:13

Faron Pharmaceuticals To Focus On Colorectal Cancer In Clevegen Trial

LONDON (Alliance News) - Faron Pharmaceuticals Oy is to target colorectal cancer in its upcoming test programme for Clevegen, it said Thursday.The testing of Clevegen on patients with will

Read more
11 Apr 2019 11:22

Faron Pharmaceuticals upbeat on latest info from MATINS trial

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Thursday that the cohort expansion part of its phase 1 and 2 'MATINS' clinical trial, investigating the safety and efficacy of its wholly-owned novel precision cancer immunotherapy 'Clevegen', would begin with patients suffering from late-stage colorectal cancer as soon as the optimal dosing was determined.

Read more
26 Mar 2019 15:52

UPDATE: Faron Pharmaceuticals Raises EUR3.1 Million In Fundraise (ALLISS)

LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday afternoon said it has raised EUR3.1 million pursuant to a placing announced earlier in the day.The company issued

Read more
26 Mar 2019 12:05

Faron Pharmaceuticals Optimistic For Traumakine As It Plans Fundraise (ALLISS)

LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday said it expects further disappointing results from Traumakine, as it plans a share placing.Faron is currently for

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.